Neoadjuvant pyrotinib for HER2 (IHC 2+/FISH+)/HR+ breast cancer with early non-response: a case report and literature review

Neoadjuvant therapy (NAT) has been widely adopted in the multimodal management of HER2-positive breast cancer. Trastuzumab and pertuzumab (HP) combined with chemotherapy is the recommended neoadjuvant regimen for patients with HER2-positive locally advanced breast cancer. Achieving total pathologica...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jiani Liu, Xinyu Peng, Xuhui Huang, Jirui Sun, Dan Geng
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2026-07-01
Saila:	Frontiers in Medicine
Gaiak:	breast cancer HER2-positive neoadjuvant non-response pyrotinib
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fmed.2026.1805199/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!